ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 117 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $340,594 | -74.4% | 64,142 | -54.1% | 0.00% | – |
| Q2 2023 | $1,331,837 | +36.4% | 139,752 | +57.4% | 0.00% | – |
| Q1 2023 | $976,569 | -65.9% | 88,779 | -54.1% | 0.00% | -100.0% |
| Q4 2022 | $2,861,003 | +535.8% | 193,311 | +720.1% | 0.00% | – |
| Q3 2022 | $450,000 | +26.1% | 23,572 | +41.0% | 0.00% | – |
| Q2 2022 | $357,000 | -65.9% | 16,719 | -69.2% | 0.00% | – |
| Q1 2022 | $1,046,000 | -7.8% | 54,302 | -0.7% | 0.00% | – |
| Q4 2021 | $1,134,000 | +57.5% | 54,663 | +81.3% | 0.00% | – |
| Q3 2021 | $720,000 | +133.0% | 30,155 | +167.1% | 0.00% | – |
| Q2 2021 | $309,000 | -47.7% | 11,290 | -44.8% | 0.00% | – |
| Q1 2021 | $591,000 | +3183.3% | 20,446 | +3235.4% | 0.00% | – |
| Q3 2020 | $18,000 | -80.9% | 613 | -80.3% | 0.00% | – |
| Q2 2020 | $94,000 | -51.3% | 3,110 | -51.9% | 0.00% | – |
| Q1 2020 | $193,000 | – | 6,468 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |